Vigil Neuroscience shares slide 10% in market debut (update)
Kraivuttinun/iStock via Getty Images


Vigil Neuroscience (VIGL) shares fell 10% following the biotech stock's market debut on Friday.
The stock ended its first session at $12.65 per share.
VIGL priced 7M shares at $14 per share, with the deal expected to generate gross proceeds of $98M. Underwriters were granted an option to purchase an additional 1.05M shares to cover any overallotments.

Shares of Vigil (VIGL) were trading at $12.40 shortly before 2 p.m. ET Friday after opening at $12.
Vigil Neuroscience is developing novel therapeutics for neurogenerative diseases with assets in-licensed from Amgen (NASDAQ:AMGN).